Alterola Biotech(OTC) ABTI

Market Cap$291.90K

Since IPO (2021)-100%

5 Year-100%

1 Year-100%

1 Month-96%

$0.00

+0.00%

+0.00Today

Alterola Biotech last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-14

Alterola Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-96.08%	USD 0.01	2026-03-30
1 month	-96.08%	USD 0.01	2026-03-30
3 month	-96.08%	USD 0.01	2026-03-30
Year to date	-96.08%	USD 0.01	2025-12-30
1 year	-99.9%	USD 0.20	2025-06-17
3 year	-98.18%	USD 0.01	2023-07-12
5 year	-99.99%	USD 2.00	2021-07-14
Since inception	-99.98%	USD 1.15	2021-06-15

Alterola Biotech Financials at a Glance

Market Cap

$291.90K

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.20M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

31.83 (High)

Dividend

$0.00

Beta (Volatility)

31.83 (High)

Price

$0.00

Volume

5,000

Open

$0.00

Price

$0.00

Volume

5,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Nov 27, 2025

Dividend

$0.00

Beta (Volatility)

31.83 (High)

Price

$0.00

Volume

5,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Nov 27, 2025

ABTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterola Biotech

Alterola Biotech, Inc. is a pharmaceutical company focused on the research and development of cannabinoid and cannabinoid-like molecules. The company aims to create regulated pharmaceutical products for both human and animal health, alongside regulated food items.

Products and Services

Research and development of cannabinoid-based pharmaceuticals
Production of active pharmaceutical ingredients (APIs)
Advanced drug formulation and delivery systems

Growth Outlook

Focus on expanding product offerings in the cannabinoid market
Potential for increased demand in regulated pharmaceutical products
Strategic initiatives aimed at enhancing bioavailability and stability

Financial Highlights

Recent quarterly net income of -$123,155
Trailing twelve months (TTM) revenue of $0
Current ratio of 0.11 indicates liquidity challenges

Alterola Biotech, Inc. operates in the specialized field of cannabinoid pharmaceuticals, which is gaining traction in the healthcare sector. The company's commitment to developing innovative products positions it well for future growth, especially as the demand for cannabinoid-based therapies continues to rise. Despite recent financial challenges, including a net income loss in the latest quarter, the focus on research and development may yield significant long-term benefits. The current ratio suggests liquidity issues, which may require careful management as the company navigates its growth trajectory. Overall, Alterola Biotech, Inc. presents an intriguing opportunity for investors interested in the evolving pharmaceutical landscape.

AI Generated • Jul 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

David John Hitchcock

Website

alterola-abti.com

Headquarters

Birkenhead, MR CH41 5AR, GB

ABTI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-14.67%

Return on Capital

-16.48%

Return on Assets

-12.46%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$291.90K

Shares Outstanding

1.46B

Volume

5.00K

Avg. Volume

79.365

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.32M

EBITDA

-$1.11M

Operating Cash Flow

-$874.20K

Capital Expenditure

-$18.90K

Free Cash Flow

-$893.10K

Cash & ST Invst.

$9.10K

Total Debt

$1.55M

Alterola Biotech Performance Analysis

Alterola Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-03-31	USD 0	N/A
2023	2023-03-31	USD 0	N/A
2024	2024-03-31	USD 0	N/A

Alterola Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2022-12-31	N/A
Q4	2023-03-31	N/A
Q1	2023-06-30	N/A
Q2	2023-09-30	N/A

Alterola Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-03-31	USD -0.01	N/A
2023	2023-03-31	USD -0.00	-69.0%
2024	2024-03-31	USD -0.00	-11.5%

Alterola Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2022-12-31	-40.0%
Q4	2023-03-31	128.6%
Q1	2023-06-30	-550.0%
Q2	2023-09-30	77.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$291.90K

N/A

Market Cap/Employee

$291.90K

N/A

Employees

N/A

Net Income

-$123.16K

+67.2%

EBITDA

-$123.16K

+73.8%

Quarterly Fundamentals

Name

Q2 2024YOY CHG

Total Cash

$9.10K

-39.8%

Total Debt

$1.55M

+204.4%

Accounts Receivable

-$9.10K

-125.4%

Inventory

$975.00

+9.2%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.55M

+317.2%

Return on Assets

-12.46%

N/A

Return on Invested Capital

-18.51%

N/A

Free Cash Flow

-$122.16K

+38.1%

Operating Cash Flow

-$122.16K

+38.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NIKANika Pharmaceuticals Inc.

NIKANika Pharmaceuticals Inc.$0.21-72.39%

CMVLFCellectis S.A.

CMVLFCellectis S.A.$3.47+12.66%

EDTXFSpectral Medical Inc

EDTXFSpectral Medical Inc$0.99-0.60%

CPHRFCipher Pharmaceuticals Inc.

CPHRFCipher Pharmaceuticals Inc.$11.94+3.38%

DMTRF3-D Matrix, Ltd.

DMTRF3-D Matrix, Ltd.$2.50+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About ABTI

What is the current price of Alterola Biotech?

Alterola Biotech is trading at $0.00 per share.

What is the 52-week range for Alterola Biotech?

Over the past 52 weeks, Alterola Biotech has traded between $0.00 and $0.20.

How much debt does Alterola Biotech have?

As of the most recent reporting period, Alterola Biotech reported total debt of $2.35M.

How much cash does Alterola Biotech have on hand?

Alterola Biotech reported $82.72K in cash and cash equivalents in its most recent financial results.

What is Alterola Biotech’s dividend yield?

Alterola Biotech does not currently have a dividend yield.

Alterola Biotech(OTC) ABTI

Alterola Biotech Financials at a Glance

ABTI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Alterola Biotech

ABTI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Alterola Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ABTI

What is the current price of Alterola Biotech?

What is the 52-week range for Alterola Biotech?

How much debt does Alterola Biotech have?

How much cash does Alterola Biotech have on hand?

What is Alterola Biotech’s dividend yield?

Premium Investing Services